David Stenehjem, PharmD, BCOP

Associate Professor and Associate Department Head, Department of Pharmacy Practice and Pharmaceutical Sciences

David Stenehjem

Contact Info


Office Phone 218-726-6155

Mobile Phone 218-428-4714

Office Address:
213 Life Science
1110 Kirby Drive
Duluth, MN, 55812

Administrative Assistant Name
Vicki Everett

Administrative Phone

Administrative Email

Associate Professor and Associate Department Head, Department of Pharmacy Practice and Pharmaceutical Sciences

Hematology/Oncology Pharmacy Specialty Resident, Post Graduate Year Two: Huntsman Cancer Hospital at the University of Utah Hospitals and Clinics, 2011

Pharmacy Practice Resident, Post Graduate Year One: University of Utah Hospitals and Clinics, 2010

PharmD, University of Minnesota, College of Pharmacy-Duluth, 2009


Professional Associations

American Society of Clinical Oncology (2015-present)

American Pharmacists Association (2005 to 2012)

American Society of Heath-System Pharmacists (2005 to 2012)

Hematology/Oncology Pharmacy Association (2010 to present)

Minnesota Pharmacy Student Alliance (2005 to 2009)

Minnesota Society of Health-System Pharmacists (2005 to 2009)

Rho Chi Academic Honors Society in Pharmacy (2006-2009)

Utah Society of Health-System Pharmacists (2009 to present)



Published peer reviewed:

1. Bailey EB, Tantravahi SK, Poole A, Wells CE, Batten JA, Merriman J, Stenehjem DD (co-senior author), Agarwal N. Association of hand-foot syndrome, treatment dose reductions, and outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor tyrosine kinase inhibitors. Journal of Oncology Practice. [Accepted for publication]

2. Au T, Wang K, Stenehjem DD, Garrido-Laguna I. Personalized and Precision Medicine: Integrating Genomics into Treatment Decisions. Journal of Gastrointestinal Oncology [Accepted for publication]

3. Gill DM, Gaston D, Bailey E, Hahn AW, Gupta S, Batten J, Alex A, Boucher K, Stenehjem DD, Agarwal N. Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone. Clinical Genitourinary Cancer. 2017 Jan 5. doi:10.1016/j.clgc.2016.12.008.

4. Kuzman, JA, Stenehjem DD (co-first author), Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N, Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology; 2017 Jan 3;17(1):1–5. doi:10.1186/s12894-016-0192-0.

5. Stenehjem DD, Udomaksorn S, Cheng Y, Pflieger L, Au TH, Buys SS, Brixner DI. Evaluation of the relevance and access of EHR-based variables to support personalized medicine in breast cancer. Schumacher U, editor. Cogent Medicine. Cogent; 2016 Oct 3;3(1). doi: 10.1080/2331205x.2016.1234661.

6. Gill DM, Stenehjem DD (co-first author), Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. ecancer. 2016;10:676. doi:10.3332/ecancer.2016.676.

7. Au TH, Cavalieri CC, Stenehjem DD. Ceritinib: A primer for pharmacists. J Oncol Pharm Pract. 2016 Oct 13. doi:10.1177/1078155216672315. 

8. Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother. 2016 Jun 8. doi:10.1007/s00262-016-1854-1.

9. Akoum N, Bader F, Ghanem M, Stenehjem DD, Burningham Z, Sauer BC. Comparison of the effectiveness and side effects of dofetilide and dronedarone in the treatment of atrial fibrillation during an indicated period in time with perceived equipoise. F1000Res. 2016;5:216. doi:10.12688/f1000research.7908.1.

10. Unni S, Schauerhamer M, Deka R, Tyczynski J, Fernandes, A, Stevens V, Brixner DI, Stenehjem DD. BRCA Testing, Treatment Patterns and Survival in Platinum-Sensitive Recurrent Ovarian Cancer – An Observational Cohort Study. Journal of Ovarian Research. 2016 Jan 1;9(1):18–8. doi:10.1186/s13048-016-0227-x.

11. Shiven PB, Stenehjem DD (co-first author), Tantravahi SK, Gill DM, Agarwal AA, Hsu J, Vuong W; Pal SK, Neeraj Agarwal. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical Genitourinary Cancer. 2015;0(0). doi:10.1016/j.clgc.2015.12.011.

12. Rochau, U, Kluibenschaedl, M, Stenehjem, DD, Kuan-Ling, K, Radich, J, Oderda, G, Brixner, D, Siebert. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. Leukemia Research and Treatment. 2015:1-13. doi:10.1155/2015/982395.

13. Stenehjem DD, Bellows BK, Yager KM, et al. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. Oncologist. November 2015. doi:10.1634/theoncologist.2015-0162.

14. Bailey H, Stenehjem DD, Sharma S. Panobinostat for the treatment of multiple myeloma: the evidence to date. Journal of Blood Medicine. October 2015:269-276. doi:10.2147/JBM.S69140

15. Kuo KL, Stenehjem DD, Albright F, Brixner DI. Treatment Patterns and Outcomes in Patients with Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. Journal of the National Comprehensive Cancer Network. 2015;13(8):987-994.

16. Siebert U, Jahn B, Rochau U, et al. on behalf of the Oncotyrol HTA & Outcomes Research Working Group. Oncotyrol – Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. July 2015. doi:10.1016/j.zefq.2015.06.012.

17. Tantravahi SK, Albertson D, Agarwal AM, Straubhar AM, Poole A, Ravulapati S, Hawatmeh JS, Liu T, Stenehjem DD (co-senior author), N Agarwal. Survival outcomes and tumor IMP3 expression in patients with sarcomatoid metastatic renal cell carcinoma. Journal of Oncology. 2015;2015(2):1–6.

18. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem DD, Brixner D, Radich J, Gastl G, Siebert U. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leukemia and Lymphoma. 2015:1–11. doi:10.3109/10428194.2014.982635.

19. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Wells CE, Stenehjem DD (co-senior author), N Agarwal. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clinical Genitourinary Cancer. 2014. doi: 10.1016/j.clgc.2014.11.002.

20. Reese R, Patel S, Stenehjem DD, Garrido-Laguna I. Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. Journal of Gastrointestinal Cancers. 2014. doi:10.1007/s12029-014-9662-3.

21. Stenehjem DD, Yoo M, Unni S, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI. Assessment of single-institution HER2 testing patterns, rate of HER2+ disease and utilization of trastuzumab in early breast cancer. Breast Cancer: Targets and Therapy. 2014:6 169–177.

22. Stenehjem DD, Albright FS, Kuo K-L, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI. Response Monitoring, Tolerability and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database. J Natl Compr Canc Netw. 2014;12(8):1113–11521

23. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014; 89(2):203-212.24. Nelson RE, Stenehjem DD, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer. 2013; 89(3):461-468.

25. Kuo K-L, Saokaew S, Stenehjem DD. The Pharmacoeconomics of Breakthrough Cancer Pain. J Pain Palliat Care Pharmacother. 2013; 27(2):167-175.

26. Saverno KR, Rochau PU, Stenehjem DD, Morley K, Siebert U, Brixner DI. Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. JMCP. 2012;18(6):1–7.

27. Gilreath JA, Stenehjem DD, Rodgers GM. Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+? J Natl Compr Canc Netw. 2012;10(5):669–676.

28. Cirulli J, McMillian WD, Saba M, Stenehjem DD. Adaptive trial design: Its growing role in clinical research and implications for pharmacists. Am J Health Syst Pharm. 2011;68(9):807–813.

29. Stenehjem DD, Hartz AMS, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med Chem. 2009;1(9):1623–1641.

30.Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW. Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009;150(2):1025–1032.

Published editorial contributions:

1. Brixner DI, Stenehjem DD, Ulrich C. Aspirin and Cancer Risk. JAMA Oncol. 2016 Aug 11.



Course Master:

Cancer Camp Elective, PCTH 5645 (Summer 2014-2016)

Oncology Module Leader, PCTH 7312

College of Pharmacy Lectures:

Data Integrity and Management: Research Ethics Seminar, PCTH 6500 (Fall 2013-present)

Practical Applications of Pharmacoeconomics: Pharmacotherapy Outcomes Research, PCTH 7150 (Spring 2011-present)

Pharmacogenomics in Oncology: Applied Pharmacokinetics, PHCEU 7316 (Spring 2013-present)

CYP450 and Drug Transporter Interactions: Applied Pharmacokinetics, PHCEU 7316 (Spring 2010-present)

Introduction to Oncology: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2013)

Lymphomas: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2013-present)

Supportive Care: Non-GI Toxicities: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2011-2012)

Supportive Care: GI Toxicities: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2010)

Prostate Cancer: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2010)

Colorectal Cancer: Diseases and Drug Therapy III—Oncology Module, PCTH 7312 (Fall 2015-present)

School of Medicine Lectures:

Pharmacogenomics in Oncology: Foundations in Personalized Health Care, MDCRC 6150 (Spring 2012)

Outcomes Research and Personalized Health Care: Foundations in Personalized Health Care, MDCRC 6150 (Spring 2012)

Principles of Anticancer Pharmacotherapy: Molecules, Cells, and Cancer, Spring 2016

Alkylating Agents and Antimetabolites: Molecules, Cells, and Cancer, Pharmacology, Spring 2016

Targeted Anticancer Therapy: Molecules, Cells, and Cancer, Pharmacology, Spring 2016

Natural Product Chemotherapy and Endocrine Therapy: Molecules, Cells, and Cancer, Pharmacology, Spring 2016

Huntsman Pharmacy Lecture Series:

Dialogue Replaces Monologue: Heterotypic Interactions: Biology of Cancer for PGY2 Oncology Residents (Spring 2012-present)

Biology of Angiogenesis: Biology of Cancer for PGY2 Oncology Residents (Spring 2012-present)

Maintenance of Genomic Integrity and the Development of Cancer: Biology of Cancer for PGY2 Oncology Residents (Spring 2012-present)

Acute Myeloid Leukemia: Resident Conference for PGY2 Oncology Residents (Fall 2010-present)

Oncology Terminology and Clinical Trial Endpoints: Resident Conference for PGY2 Oncology Residents (Fall 2010-present)


Winter School in Clinical Epidemiology, Teaching Assistant: UMIT - The Health & Life Sciences University Hall i.T., Austria. (Winter 2013)


Board Certifications

Board Certified Oncology Specialist, Board of Pharmacy Specialties